Whitehawk Therapeutics (WHWK) Insider Hirmand Buys 38,040 Shares

Mohammad Hirmand joined a significant group of insiders at Whitehawk Therapeutics, Inc. (WHWK) by acquiring 38,040 shares on June 12, 2026. This transaction was part of a broader cluster of buying activity where six other individuals associated with the company also added exactly 38,040 shares to their holdings on the same day.

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

The buying spree on June 12, 2026, included Behzad Aghazadeh, Baiteng Zhao, Richard Maroun, Emma Reeve, Neil Desai, and Caley Castelein. Each of these individuals purchased 38,040 shares. These transactions were not conducted under a Rule 10b5-1 plan, which is a pre-set schedule insiders sometimes use to trade at specific times. The uniform size of these buys across the board indicates a coordinated entry or participation in a recent offering by the clinical-stage biotech firm.

Whitehawk Therapeutics Stock Performance

Shares of Whitehawk Therapeutics were trading at $4.16 on Tuesday. The stock has spent much of the year recovering from a 52-week low of $1.82, though it remains below its 52-week high of $5.50. Currently, the price is hovering just under its 50-day moving average of $4.29 but remains comfortably above its 200-day moving average of $3.71, a common indicator of long-term trend health. With a market capitalization of $230.3 million, the company is valued as a small-cap player in the oncology space.

Analysts Set New Price Targets

Several investment firms have recently started following the company with optimistic views. On October 1, 2026, Stifel began coverage with a Buy rating and a $9.00 price target. This followed Leerink Partners, which initiated an Outperform rating on July 13, 2026, also with a $9.00 target. B. Riley Securities has been even more bullish, setting a $10.00 price target on June 25, 2026. Across the six analysts who provide opinions on the stock, the consensus is a Buy with a mean price target of $7.50.

Recent Financial Results

Whitehawk Therapeutics is a biotechnology company focused on developing antibody-drug conjugates to treat various cancers. Because the company is still in the clinical stages of testing its treatments, it does not yet have a meaningful P/E ratio and reported a loss of $1.21 per share. The company maintains a high level of liquidity to fund its research, evidenced by a current ratio of 17.38. Investors are looking toward November 5, 2026, when the company is expected to release its next quarterly financial update.

What's Ahead for Whitehawk Therapeutics, Inc.

The cluster of insider buying in June arrived just before a string of positive analyst initiations through the summer and fall. While these insider trades provide a glimpse into how leadership viewed the company's value in June, they are backward-looking reports. Market participants will likely focus on the upcoming November earnings report for updates on the company's oncology portfolio and clinical trial progress.